

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Fernando DOÑATE et al.

Serial. No. 10/074,225

Filed: February 14, 2002

For: HISTIDINE PROLINE RICH GLYCOPROTEIN

(HPRG) AS AN ANTIANGIOGENIC AND

**ANTI-TUMOR AGENT** 

Art Unit: 1642

Examiner: David Blanchard

New Atty. Docket No. 28932.0004

Customer No.

30827

## RESPONSE AND AMENDMENT UNDER 37 CFR §1.111

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Dear Sir:

This paper responds to the Non-Final Office Action mailed November 17, 2004, the response to which is extended two months to April 18, 2005 (the April 17, 2005, due date having fallen on a weekend) with the accompanying Petition for Extension of Time and a payment of the extension fee.

Applicants submit herewith the following additional documents:

- (a) A Declaration under 37 CRF §1.131 of Fernando Doñate;
- (b) An after filing publication by Fernando Doñate and colleagues<sup>1</sup>.

Please amend the above-identified application as follows: **Amendments to the Claims** are reflected in the Listing of Claims, which begins on page 2 of this paper. **Applicants' REMARKS** begin on page 10.

<sup>&</sup>lt;sup>1</sup> Doñate et al., "Peptides Derived from the H-P Domain of the HPRGT Glycoprotein Bind to Tropomyosin and Have Antiangiogenic and Antitumor Activities, Cancer Resea4rch 64:5812-5817 (2004).